Sarah Cannon Outcomes Registry
- Conditions
- Oncology
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT02356822
- Locations
- ๐บ๐ธ
SCRI, Nashville, Tennessee, United States
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02318784
- Locations
- ๐บ๐ธ
Oncology Hematology Care, INC., Cincinnati, Ohio, United States
๐บ๐ธRocky Mountain Cancer Center, Denver, Colorado, United States
๐บ๐ธFlorida Cancer Specialists - North, Saint Petersburg, Florida, United States
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
- Conditions
- Gastroesophageal Cancer
- Interventions
- Biological: ramucirumab
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 65
- Registration Number
- NCT02317991
- Locations
- ๐บ๐ธ
Tennessee Oncology, Chattanooga, Tennessee, United States
๐บ๐ธResearch Medical Center, Kansas City, Missouri, United States
๐บ๐ธIngalls Cancer Research Center, Harvey, Illinois, United States
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT02300935
- Locations
- ๐บ๐ธ
Colorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธFlorida Cancer Center, Sarasota, Florida, United States
๐บ๐ธTennessee Oncology PLLC, Nashville, Tennessee, United States
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- ๐บ๐ธ
Woodlands Medical Specialists, Pensacola, Florida, United States
๐บ๐ธHope Cancer Center, Terre Haute, Indiana, United States
๐บ๐ธCenter for Cancer and Blood Disorders, Fort Worth, Texas, United States
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT02254551
- Locations
- ๐บ๐ธ
Colorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธOncology Hematology Care, Cincinnati, Ohio, United States
๐บ๐ธTennessee Oncology, Chattanooga, Tennessee, United States
Safety Study of Regorafenib and SIR-Spheresยฎ Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02195011
- Locations
- ๐บ๐ธ
Tennessee Oncology PLLC, Nashville, Tennessee, United States
๐บ๐ธFlorida Cancer Specialists - North, Saint Petersburg, Florida, United States
๐บ๐ธResearch Medical Center, Kansas City, Missouri, United States
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02168101
- Locations
- ๐บ๐ธ
Oncology Hematology Care, Cincinnati, Ohio, United States
๐บ๐ธTennessee Oncology PLLC, Nashville, Tennessee, United States
๐บ๐ธTexas Transplant Institute, San Antonio, Texas, United States
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02125084
- Locations
- ๐บ๐ธ
Tennessee Oncology, Chattanooga, Tennessee, United States
๐บ๐ธTennessee Oncology PLLC, Nashville, Tennessee, United States
๐บ๐ธFlorida Cancer Specialists, Fort Myers, Florida, United States
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02113007
- Locations
- ๐บ๐ธ
Memorial Cancer Institute, Hollywood, Florida, United States
๐บ๐ธYale School of Medicine, New Haven, Connecticut, United States
๐บ๐ธFlorida Hospital Cancer Institute, Orlando, Florida, United States